Completed PHASE2 INTERVENTIONAL NCT00145366

rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter

Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials.

Sponsor: Odense University Hospital

Conditions Benign Nontoxic and Toxic Goiter Graves' Disease

Interventions Recombinant human thyrotropin (Thyrogen)

Updated 5 times since 2017 Last updated: Dec 27, 2010 Started: Apr 30, 2002 Completion: Jul 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Benign Nontoxic and Toxic Goiter and Graves' Disease, this trial is completed. The trial is conducted by Odense University Hospital and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Odense University Hospital

Data source: Odense University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Odense, Denmark